Skip to main content

RenovoRx, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

RNXT$1.18+4.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

Incorporated by Reference
Exhibit NumberExhibit DescriptionFormFile No.ExhibitFiling Date
3.1Sixth Amended and Restated Certificate of Incorporation of RenovoRx, Inc.8-K001-407383.1August 31, 2021
3.2Amended and Restated Bylaws of RenovoRx, Inc.8-K001-407383.1September 11, 2023
4.1Specimen Stock Certificate evidencing the Shares of Common StockS-1333-2580714.4August 5, 2021
4.2Form of Pre-Funded Common Stock Purchase Warrant8-K001-407384.1April 3, 2023
4.3Form of Common Stock Purchase Warrant8-K001-407384.2April 3, 2023
4.4Warrant to Purchase Common Stock of RenovoRx, Inc.8-K001-4073810.3January 29, 2024
4.5RenovoRx Placement Agent Warrant8-K001-4073810.5January 29, 2024
4.6Form of Pre-Funded Common Stock Purchase Warrant of RenovoRx, Inc.8-K001-4073810.2April 15, 2024
4.7Form of Series A Warrant to Purchase Common Stock of RenovoRx, Inc.8-K001-4073810.3April 15, 2024
4.8Form of Placement Agent Warrant to Purchase Common Stock of RenovoRx, Inc.8-K001-4073810.5April 15, 2024
4.9Form of Underwriter Warrant issued in February 2025 Public Offering8-K001-407384.1February 10, 2025
4.10Form of Pre-Funded Warrant Issued to Investors in the March 2026 Private Placement8-K001-407384.1March 23, 2026
4.11Form of Milestone Warrant Issued to Investors in the March 2026 Private Placement8-K001-407384.2March 23, 2026
10.1+Amended and Restated 2021 Omnibus Equity Incentive Plan8-K001-4073810.1June 30, 2026
10.2+Amended and Restated Outside Director Compensation PolicyFiled herewith
31.1Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Filed herewith
31.2Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Filed herewith
32.1†Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Furnished herewith
32.2†Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Furnished herewith
101.INSInline XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL documentFiled herewith
101.SCHInline XBRL Taxonomy Extension Schema with Embedded Linkbase DocumentsFiled herewith
104Cover Page formatted as Inline XBRL and contained in Exhibit 101Filed herewith
  • Indicates management contract or compensatory plan or arrangement.

† The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.